Document is current
Any future updates will be listed below
-
Authors
Maciel, Carolina B. https://orcid.org/0000-0002-8763-5839
Teixeira, Fernanda J. P.
Dickinson, Katie J.
Spana, Jessica C.
Merck, Lisa H.
Rabinstein, Alejandro A.
Sergott, Robert
Shan, Guogen
Miao, Guanhong
Peloquin, Charles A.
Busl, Katharina M.
Hirsch, Lawrence J.
-
Funding
Funding for this research was provided by:
American Heart Association (Innovative Project Award 20IPA35380013)
- License Information
-
More Information
Article History
Received: 8 December 2021
Accepted: 30 December 2021
First Online: 24 January 2022
Declarations
:
: Informed consent from a legal authorized representative, including counseling and enrollment required in accordance with Risk Evaluation and Mitigation Strategies (REMS) program by a certified REMS physician, will be obtained for all patients prior to vigabatrin administration and signed by the investigator seeking the consent. The study will be explained described to the legal authorized representative in an appropriately considerate manner by the principal investigator or certified REMS physician co-investigator, and the legal authorized representative will have opportunity to ask additional clarifying questions.
: All authors listed above consent for the publication of the information enclosed in this manuscript.
: The authors have no competing interests.
